103 related articles for article (PubMed ID: 7794700)
1. Nizatidine versus placebo in gastro-oesophageal reflux disease: a 6-week, multicentre, randomised, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study Group.
Cloud ML; Offen WW
Br J Clin Pract Suppl; 1994 Nov; 76():11-9. PubMed ID: 7794700
[TBL] [Abstract][Full Text] [Related]
2. Nizatidine versus placebo in gastro-oesophageal reflux disease: a 12-week, multicentre, randomised, double-blind study.
Cloud ML; Offen WW; Robinson M
Br J Clin Pract Suppl; 1994 Nov; 76():3-10. PubMed ID: 7794701
[TBL] [Abstract][Full Text] [Related]
3. Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study.
Cloud ML; Offen WW; Robinson M
Am J Gastroenterol; 1991 Dec; 86(12):1735-42. PubMed ID: 1962618
[TBL] [Abstract][Full Text] [Related]
4. Nizatidine versus placebo in gastroesophageal reflux disease. A six-week, multicenter, randomized, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study Group.
Cloud ML; Offen WW
Dig Dis Sci; 1992 Jun; 37(6):865-74. PubMed ID: 1587191
[TBL] [Abstract][Full Text] [Related]
5. Treatment of erosive reflux oesophagitis: a double-blind multicentre trial with nizatidine 300 mg b.i.d. versus placebo.
Dobrilla G; Chilovi F; Tafner G; Vantini I; Bernardi A; Gentilini R; Fedrizzi F; Manfrini R; Steiner H; Mon M
Ital J Gastroenterol; 1992; 24(6):338-41. PubMed ID: 1515660
[TBL] [Abstract][Full Text] [Related]
6. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
Haag S; Holtmann G
Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
[TBL] [Abstract][Full Text] [Related]
7. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children.
Orenstein SR; Gremse DA; Pantaleon CD; Kling DF; Rotenberg KS
Clin Ther; 2005 Apr; 27(4):472-83. PubMed ID: 15922820
[TBL] [Abstract][Full Text] [Related]
8. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.
Carlsson R; Dent J; Watts R; Riley S; Sheikh R; Hatlebakk J; Haug K; de Groot G; van Oudvorst A; Dalväg A; Junghard O; Wiklund I
Eur J Gastroenterol Hepatol; 1998 Feb; 10(2):119-24. PubMed ID: 9581986
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study.
Kovacs TO; Wilcox CM; DeVault K; Miska D; Bochenek W;
Aliment Pharmacol Ther; 2002 Dec; 16(12):2043-52. PubMed ID: 12452936
[TBL] [Abstract][Full Text] [Related]
10. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
Bautista J; Fullerton H; Briseno M; Cui H; Fass R
Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
[TBL] [Abstract][Full Text] [Related]
11. Cimetidine QID and BID in rapid heartburn relief and healing of lesions in gastroesophageal reflux disease.
Palmer RH; Miller DM; Hedrich DA; Karlstadt RG
Clin Ther; 1993; 15(6):994-1001. PubMed ID: 8111819
[TBL] [Abstract][Full Text] [Related]
12. Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial.
Sontag S; Robinson M; McCallum RW; Barwick KW; Nardi R
Arch Intern Med; 1987 Aug; 147(8):1485-91. PubMed ID: 3307670
[TBL] [Abstract][Full Text] [Related]
13. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group.
Sabesin SM; Berlin RG; Humphries TJ; Bradstreet DC; Walton-Bowen KL; Zaidi S
Arch Intern Med; 1991 Dec; 151(12):2394-400. PubMed ID: 1746996
[TBL] [Abstract][Full Text] [Related]
14. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial.
Boeckxstaens GE; Beaumont H; Hatlebakk JG; Silberg DG; Björck K; Karlsson M; Denison H
Gut; 2011 Sep; 60(9):1182-8. PubMed ID: 21402616
[TBL] [Abstract][Full Text] [Related]
15. [Symptomatic therapy with famotidine in non-erosive gastro-esophageal reflux. Results of an open multicenter study].
Heckers H; Lübbecke F
Arzneimittelforschung; 1995 Apr; 45(4):499-504. PubMed ID: 7779150
[TBL] [Abstract][Full Text] [Related]
16. Metoclopramide in gastroesophageal reflux disease: rationale for its use and results of a double-blind trial.
McCallum RW; Fink SM; Winnan GR; Avella J; Callachan C
Am J Gastroenterol; 1984 Mar; 79(3):165-72. PubMed ID: 6367434
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.
Fass R; Delemos B; Nazareno L; Kao R; Xiang J; Lu Y
Aliment Pharmacol Ther; 2010 May; 31(9):950-60. PubMed ID: 20132154
[TBL] [Abstract][Full Text] [Related]
18. Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison. The Nizatidine Benign Gastric Ulcer Disease Study Group.
Cloud ML; Enas N; Offen WW
Clin Pharmacol Ther; 1992 Sep; 52(3):307-13. PubMed ID: 1526089
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, placebo-controlled study of the effectiveness and safety of nizatidine in the prevention of postprandial heartburn.
Spiegel JE; Thoden WR; Pappas K; Fratarcangelo P; Furey SA
Arch Intern Med; 1997 Jul; 157(14):1594-9. PubMed ID: 9236562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
